← Browse by Condition
Medical Condition
refractory lupus nephritis
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for refractory lupus nephritis sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 2
Phase 2 1
Top Sponsors
1 trial
1 trial
NCT06676631 Phase 1
Recruiting
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Enrollment
18 pts
Location
China
Sponsor
Guangdong Provincial People's ...
NCT06947473 Phase 1, Phase 2
Recruiting
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Enrollment
45 pts
Location
China
Sponsor
Beijing GoBroad Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology